ArticleAnnals of maxillofacial surgery
Langerhans Cell Histiocytosis Involving the Maxilla and Mandible - A Case Report.
Article in Annals of maxillofacial surgery. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rationale: Langerhans cell histiocytosis (LCH) is a rare disease involving neoplastic proliferation of myeloid precursor cells, primarily affecting bones such as ribs, pelvis, femur, and mandible with rare simultaneous involvement of the maxilla and mandible. Patient Concerns and Diagnosis: A 48-year-old male presented with swelling and tooth mobility since 6 months. Orthopantomogram revealed extensive destruction in the mandible and right maxillary posterior region. Histological examination confirmed LCH using immunohistochemical staining with S-100, CD1a. Treatment: As patient refused of surgery, intralesional methylprednisolone injections were selected as non-invasive treatment approach for localized LCH. Outcome: Three months post-treatment, remission was observed, though some residual lesion remained. Follow-up at six months showed no further disease progression, supporting the efficacy of corticosteroid injections. Take-away Lessons: Treatment should be based on the diagnosis of LCH along with the extent of involvement of bones. Based on review of the literature and our own findings, intralesional corticosteroids were found to be effective for localized LCH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.